ADDF in the News

Dr. Howard Fillit provides commentary on Biogen's decision to abandon Aduhelm, noting how this was more of a commercial than a scientific decision, and offering insights on how the handling of the program led to uncertainty about the drug.

In an article on blood-based biomarkers, Dr. Howard Fillit is quoted throughout, citing the JPAD Special Edition featuring ADDF-funded scientists and the future of lab-developed tests (LDTs), as well as the importance of biomarkers for precision medicine and how this treatment approach will be the key to reaching 100% slowing of cognitive decline.

Dr. Howard Fillit weighs in on the FDA’s decision to hold an Advisory Committee for donanemab, noting that the decision isn’t a setback, but rather the agency doing its due diligence, and offers background on the trial design.

Dr. Howard Fillit discusses the unique design of Lilly’s TRAILBLAZER-ALZ 2 trial for donanemab, with a focus on the stopping rules and tau imaging.

With the recent FDA decision to hold an Advisory Committee to discuss donanemab, Dr. Howard Fillit weighs in on the drug’s safety profile and novel trial design, which will likely be the focus of the meeting.